Tectonic completed enrollment of 191 patients in APEX, a Phase 2 trial testing TX45, an Fc-relaxin fusion protein, for pulmonary hypertension associated with heart failure with preserved ejection fraction. The study targets a subset with elevated pulmonary vascular resistance, representing a population at high risk for progressive cardiac dysfunction and mortality.
Key Points
- 191 patients enrolled across 14 countries; 137 met PVR threshold criteria
- TX45 designed to produce vasodilatory, anti-fibrotic, anti-inflammatory effects
- Primary endpoint: change in pulmonary vascular resistance; results expected Q1 2027
Longevity Analysis
Heart failure with preserved ejection fraction represents a growing segment of heart disease mortality, particularly in aging populations, because standard therapies offer limited benefit. TX45's mechanism—activating RXFP1 to induce vasodilation and reduce pathological fibrosis—addresses a fundamentally different pathway than current standard care, potentially restoring vascular and cardiac reserve in patients where conventional interventions have plateaued. Success in this trial would demonstrate that selective receptor agonism can reverse the microvascular and tissue-level changes that drive progression, opening a treatment option for a condition historically associated with poor long-term outcomes.
Original published by LT Wire.